Share on LinkedInShare on LinkedIn

ARTICLE · 26 JUNE 2014

"I Shouldn’t Copy, Right?" Why Pharmaceutical Companies Should Care About Copyright

Borden Ladner Gervais LLP
Borden Ladner Gervais LLP
Contributor
Borden Ladner Gervais LLP

Borden Ladner Gervais LLP

With over 750 lawyers, intellectual property agents and other professionals, BLG services...

View firm profile
Explore more from Borden Ladner Gervais LLP

In the pharmaceutical industry, the issue of copyright can arise in the context of product monographs.

CanadaIntellectual Property

The Product Monograph

In the pharmaceutical industry, the issue of copyright can arise in the context of product monographs. Once approved by Health Canada, product monographs are publicly available documents and contain the information for safe and effective use of a drug. It is drafted and redrafted as Health Canada and the drug manufacturer discuss the product and exchange information. A final approved product monograph may not include all of the information exchanged between the parties, but is the result of discussions and compromise between them. It is published as part of the Notice of Compliance ("NOC") issued by Health Canada and without it, the drug product cannot be sold.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from